Samsung Bio polypeptide acquisition ranked 6th... SK Biopharmaceuticals ranks 7th in new drug introduction

Samsung Bio polypeptide acquisition ranked 6th... SK Biopharmaceuticals ranks 7th in new drug introduction

Hanmi Pharmaceutical ranked 9th in technology exports… 3 out of 10 Asia-Pacific influence deals: Korea

(Seoul = Yonhap News) Reporter Shin Seon-mi = Among the 10 'impactful deals' signed by pharmaceutical and bio companies in the Asia-Pacific region this year, three domestic cases were included.

The Korea Biotechnology Association announced this on the 5th, citing the selection information from 'Biopharma APAC', a biopharmaceutical media outlet.

According to the association, Biopharma APAC selected 10 '2026 Influential Asia Pacific Biopharmaceutical Transactions' by comprehensively evaluating transaction size and symbolism of mergers and acquisitions (M&A) and licensing agreements involving companies headquartered in the Asia Pacific region.

Among domestic cases, the acquisition of the polypeptide group by Samsung BioLogics [207940] was ranked 6th.

Biopharma APAC highly evaluated the fact that Samsung BioLogics secured raw materials and supply chain for treatments by acquiring a global peptide contract development and manufacturing (CDMO) company amid a surge in global demand for obesity and diabetes treatments.

SK Biopharmaceuticals [326030]'s introduction of 'Opakalim', a new epilepsy drug candidate, ranked 7th.

Biopharma APAC explained that the Korean company paid a large advance payment comparable to that of Western pharmaceutical companies and preemptively secured U.S. assets before the announcement of key clinical results.

However, he added that whether the investment was 'visionary' will be determined depending on the clinical results of this candidate material in the second half of this year.

Hanmi Pharmaceutical [128940] was ranked 9th in terms of technology exports for metabolic disease treatment candidates.

Through this contract, Hanmi Pharmaceutical receives an advance payment of $190 million from Genentech, a subsidiary of the Roche Group.

Although not included in the top 10, Biopharma APAC also paid attention to the licensing agreement Alteogen [196170] signed with Novartis.

The top 10 transactions selected by Biopharma APAC was India's Sun Pharma's acquisition of US Organon for $11.75 billion entirely in cash.